Coronary heart disease: Reducing the risk - The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 8, 1999, Pages 1819-1824

  Assmann, Gerd ^a   Cullen, Paul ^a   Jossa, Fabrizio ^b   Lewis, Barry ^c   Mancini, Mario ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Coronary heart disease; Risk factors

Indexed keywords

HOMOCYSTEINE;

CORONARY RISK; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION;

EID: 0032814073     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.8.1819     Document Type: Review

References (41)

1. Sytkowski PA, Kannel WB, d'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular diseases: the Framingham Heart Study. N Engl J Med. 1990;322:1635-1641.
2. Tunstall-Pedoe H, et al., for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedure, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612.
3. Janus ED, Postiglione A, Singh RB, Lewis B. The modernization of Asia: implications for coronary heart disease. Circulation. 1996;94:2671-2673.
4. Stehle G, Bernhardt R. Coronary Risk Factors in Japan and China. Berlin, Germany: Springer Verlag; 1987:11-13.
5. Neaton JD, Wentworth D. Serum-cholesterol, blood-pressure, cigarette-smoking, and death from coronary heart-disease: overall findings and differences by age for 316099 white men. Arch Intern Med. 1992;152: 56-64.
6. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
7. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J. 1998;19:A2-A11.
8. Crepaldi G, Tiengo A, Manzato E. The plurimetabolic syndrome. In: Crepaldi G, Tiengo A, Manzato E, eds. Diabetes, Obesity, and Hyperlipidemias. Amsterdam. Netherlands: Excerpta Medica; 1993. Chapter V. International Congress Series 1039.
9. Paffenberger RS, Wing AL, Ford RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1978;108:161-175.
10. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
11. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, deValk HW, Luis ACS, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
12. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
13. Diaz MN, Frei B, Vita JA, Keaney JF. Mechanisms of disease: antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337: 408-416.
14. Kromhout D, Menotti A, Bloemberg B, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Giaipaoli S, Jansen A, Karvonen M, Katan M, Nissinen A, Nedeljkovic S, Pekkanen J, Pekkarinen M, Punsar S, Rasanen L, Simic B, Toshima H. Dietary saturated and trans-fatty-acids and cholesterol and 25-year mortality from coronary-heart-disease: the 7 countries study. Prev Med. 1995;24:308-315.
15. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH, Kromhout D, Nedeljkovic S, Punsar S, Seccareccia F, Toshima H. The diet and 15-year death rate in the 7 countries study. Am J Epidemiol. 1986;124:903-915.
16. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275:447-451.
17. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, Sweetnam PM, Deadman NM. Effects of changes in fat, fish, and fiber intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757-761.
18. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean α-linolenic acid rich diet in secondary prevention of coronary heart-disease. Lancet. 1994;343: 1454-1459.
19. Kohlmeier L, Kark JD, Gomez-Gracia E, Martin BC, Steck SE, Kardinaal AFM, Ringstad J, Thamm M, Masaev V, Riemersma R, Martin-Moreno JM, Huttunen JK, Kok FJ. Lycopene and myocardial infarction risk in the EURAMIC Study. Am J Epidemiol. 1997;146:618-626.
20. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart-disease: the Zutphen elderly study. Lancet. 1993;342:1007-1011.
21. Cholesterol, diastolic blood-pressure, and stroke: 13000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
22. Levy D, Wilson PWF, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary heart disease: new insights from the Framingham study. Am Heart J. 1990;119:712-717.
23. Pyörälä K, De Backer G, Graham I, Poole-Wilson PA, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
24. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease: prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
25. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991; 83:356-362.
26. Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation. 1997;96:2128-2136.
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
29. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial-infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
30. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279: 1615-1622.
31. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
32. Detre KM, Shaw L. Long-term changes of serum cholesterol with cholesterol-altering drugs in patients with coronary heart disease: Veterans Administration Drug-Lipid Cooperative Study. Circulation. 1974;50: 998-1005.
33. World Health Organisation. Hypertension Control: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1996; WHO technical report series 862.
34. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
35. Staessen JA, Fagard R, Thijs L, Celis H, Birkenhager WH, Bulpitt CJ, deLeeuw PW, Fletcher AE, Babarskiene MR, Forette F, Kocemba J, Laks T, Leonetti G, Nachev C, Petrie JC, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Zanchetti A. Subgroup and per-protocol analysis of the randomized European Trial on isolated systolic hypertension in the elderly Arch Intern Med. 1998;158:1681-1691.
36. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program, SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741-751.
37. Taubes G. The (political) science of salt. Science. 1998;281:898-907.
38. McCarron DA. Diet and blood pressure: the paradigm shift. Science. 1998;281:933-934.
39. Gent M, Beaumont D, Blanchard J, Bousser MG, Coffmann J, Easton JD, Hampton JR, Harker LA, Janzon L, Kusmierek JJE, Panak E, Roberts RS, Shannon JS, Sicurella J, Tognoni G, Topol EJ, Verstraete M, Warlow C. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
40. Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality from tobacco in developed-countries: indirect estimation from national vital-statistics. Lancet. 1992;339:1268-1278.
41. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.